Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.900
-0.200 (-4.88%)
At close: Apr 28, 2026, 4:00 PM EDT
3.890
-0.010 (-0.26%)
After-hours: Apr 28, 2026, 7:33 PM EDT
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Orchestra BioMed Holdings stock have an average target of 14.25, with a low estimate of 10 and a high estimate of 20. The average target predicts an increase of 265.38% from the current stock price of 3.90.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2026.
Analyst Ratings
The average analyst rating for Orchestra BioMed Holdings stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +412.82% | Mar 12, 2026 |
| Barclays | Barclays | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +207.69% | Jan 9, 2026 |
| TD Cowen | TD Cowen | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +284.62% | Dec 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +412.82% | Nov 13, 2025 |
| Barclays | Barclays | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | +182.05% | Nov 12, 2025 |
Financial Forecast
Revenue This Year
1.59M
from 33.48M
Decreased by -95.27%
Revenue Next Year
1.78M
from 1.59M
Increased by 12.43%
EPS This Year
-1.80
from -1.11
EPS Next Year
-1.74
from -1.80
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.8M | 4.8M | ||||||
| Avg | 1.6M | 1.8M | ||||||
| Low | 559,580 | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -85.6% | 204.7% | ||||||
| Avg | -95.3% | 12.4% | ||||||
| Low | -98.3% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.61 | -1.51 | ||||||
| Avg | -1.80 | -1.74 | ||||||
| Low | -1.94 | -2.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.